Rapport Therapeutics (RAPP) CSO Bredt sells shares under 10b5-1 plan

Rhea-AI Filing Summary

Rapport Therapeutics Chief Scientific Officer David Bredt reported selling common stock in the company. On January 15, 2026, he sold 8,300 shares of common stock at a weighted average price of $26.8255 and an additional 200 shares at $27.40. The weighted average sale was executed in multiple trades at prices ranging from $26.33 to $27.30. After these sales, Bredt beneficially owned 395,575 shares of common stock directly. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024, which is designed to allow insiders to sell shares according to a preset schedule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bredt David

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		S(1)		8,300	D	$26.8255(2)	395,775	D
Common Stock	01/15/2026		S(1)		200	D	$27.4	395,575	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.33 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Rapport Therapeutics (RAPP) disclose for David Bredt?

Rapport Therapeutics disclosed that Chief Scientific Officer David Bredt sold common stock in the company on January 15, 2026, in two transactions totaling 8,500 shares.

How many Rapport Therapeutics shares did David Bredt sell and at what prices?

David Bredt sold 8,300 shares at a weighted average price of $26.8255 and 200 shares at $27.40, with the larger block executed in multiple trades between $26.33 and $27.30.

How many Rapport Therapeutics shares does David Bredt own after the reported sales?

Following the reported transactions, David Bredt beneficially owned 395,575 shares of Rapport Therapeutics common stock, held directly.

Were David Bredt’s Rapport Therapeutics stock sales under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, which pre-schedules trades.

What does the weighted average price in David Bredt’s stock sale mean?

The filing explains that the $26.8255 figure is a weighted average price, reflecting multiple trades in the $26.33 to $27.30 range for the 8,300-share sale.

What is David Bredt’s role at Rapport Therapeutics?

According to the filing, David Bredt is an officer of Rapport Therapeutics and serves as the company’s Chief Scientific Officer.